Literature DB >> 25056809

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

A Morgentaler1, J McGettigan2, Q Xiang3, T M Danoff3, E M Gould3.   

Abstract

The objective of this study was to assess drying time after application of testosterone 2% gel (Fortesta Gel, Endo Pharmaceuticals), time needed for serum total testosterone (TT) to reach the eugonadal range (⩾ 300 ng dl(-1)), and time to steady-state serum TT. Thirty-four men with primary or secondary hypogonadism were enrolled in the study; 31 men were included in the pharmacokinetics (PKs) population. Testosterone 2% gel (40 mg) was applied once daily in the morning to the front and inner thighs for 14 days. Median gel drying time was 2.4 min (95% confidence interval (CI), 1.7-3.4 min; n = 31). Serum TT concentrations reached the target eugonadal range with a median time of 2.9 h (95% CI, 1.9-4.3 h; n = 24). Median time to steady-state serum TT concentration was 1.1 days (95% CI, 0.7-3.4 days; n = 31). Six patients (17.6%; n = 34) reported treatment-related adverse events; all were mild. The results from this 14-day PK study in men with hypogonadism suggest that testosterone 2% gel dries, on average, in <3 min after application and that testosterone 2% gel rapidly reaches the target eugonadal range and attains steady-state serum TT concentrations in about 1 day.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056809     DOI: 10.1038/ijir.2014.28

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  25 in total

Review 1.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

2.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

3.  Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations.

Authors:  E Nieschlag; R Swerdloff; H M Behre; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; J E Morley; C Schulman; C Wang; W Weidner; F C W Wu
Journal:  J Androl       Date:  2006 Mar-Apr

Review 4.  Male hypogonadism : an update on diagnosis and treatment.

Authors:  Emily Darby; Bradley D Anawalt
Journal:  Treat Endocrinol       Date:  2005

5.  Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Authors:  R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  A novel testosterone 2% gel for the treatment of hypogonadal males.

Authors:  Adrian S Dobs; John McGettigan; Paul Norwood; Julian Howell; Elizabeth Waldie; Yusong Chen
Journal:  J Androl       Date:  2011-10-06

Review 7.  Testosterone and metabolic syndrome: a meta-analysis study.

Authors:  Giovanni Corona; Matteo Monami; Giulia Rastrelli; Antonio Aversa; Yuliya Tishova; Farid Saad; Andrea Lenzi; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  J Sex Med       Date:  2010-08-30       Impact factor: 3.802

Review 8.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

9.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.

Authors:  Michael Jay Schoenfeld; Emily Shortridge; Zhanglin Cui; David Muram
Journal:  J Sex Med       Date:  2013-03-06       Impact factor: 3.802

View more
  1 in total

Review 1.  Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations.

Authors:  Milou Cecilia Madsen; Martin den Heijer; Claudia Pees; Nienke R Biermasz; Leontine E H Bakker
Journal:  Endocr Connect       Date:  2022-07-25       Impact factor: 3.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.